Sign in
Taking peopleNo phase

Urinary and sexual function after lymph node surgery for testicular cancer

Tracks urination and sex after lymph node surgery for testicular cancer.

Key facts

Who runs it
Jagiellonian University
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer
Status
Recruiting
People taking part
20 people, planned
Started
14 May 2025
Expected to end
Dec 2027
Type of study
Observational
Treatments tested
  • Uroflowmetry and questionnaires
Record updated
16 July 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adult men with testicular cancer who are going to have surgery to remove lymph nodes at the back of the belly (RPLND). It studies urination, erection and ejaculation before and up to 6 months after surgery.

Age
18 years and older
Sex
Men only
Disease stage
Testicular cancer for which RPLND surgery is planned
Earlier treatment
People who have had RPLND before cannot join.

Main reasons for not taking part

  • Earlier RPLND surgery
  • Not giving consent

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND)

Who cannot take part

  • History of RPLND
  • Lack of consent

This trial is currently available in Poland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate how retroperitoneal lymph node dissection (RPLND), a surgical treatment for testicular cancer, may affect urinary and sexual functions in men. RPLND involves the removal of lymph nodes from the abdominal area and is sometimes necessary in patients who are not eligible for chemotherapy or who have residual disease after chemotherapy. While this surgery is known to carry a risk of affecting ejaculation, its potential impact on other areas such as urination or erection is not well understood.

Read full original descriptionShow less

The study will prospectively follow adult men undergoing RPLND. It will assess changes in lower urinary tract symptoms, urine flow, ejaculation, erection, and overall quality of life before surgery and during follow-up visits up to 6 months after the operation. Patients will complete standardized questionnaires and undergo simple, non-invasive tests such as urine flow measurement.

By identifying how RPLND may influence urinary and sexual health, this study seeks to improve understanding of the full range of effects of this treatment. The findings may help clinicians better inform patients before surgery and support improved post-operative care.

The group in the trial

  • Adult men with testicular cancer undergoing retroperitoneal lymph node dissection

    Adult men with testicular cancer undergoing retroperitoneal lymph node dissection will have uroflowmetry performed and will complete questionnaires focusing on urinary, erectile and ejaculatory function before surgery, after surgery and during 6 months follow-up

    Treatment: Uroflowmetry and questionnaires

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Voiding, Erectile and Ejaculatory Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer
Plain-language title
Urinary and sexual function after lymph node surgery for testicular cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
16 July 2025